Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A MULTICENTER PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF BOSUTINIB VERSUS IMATINIB IN ADULT PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA

NCT02130557 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02130557
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02130557 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A MULTICENTER PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF BOSUTINIB VERSUS IMATINIB IN ADULT PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
July 15, 2014
Completion date
April 17, 2020
Enrollment
536 (actual)
Sites
189

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, myelogenous, chronic, breakpoint cluster region-abelson proto-oncogene (bcr-abl) positive